Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection
Sign Up to like & getrecommendations! Published in 2019 at "Infectious Diseases"
DOI: 10.1080/23744235.2019.1670352
Abstract: Abstract Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low-level persistent immune activation in the central nervous system (CNS). There have been concerns regarding the CNS efficacy of tenofovir alafenamide fumarate (TAF) because… read more here.
Keywords: tenofovir; nervous system; central nervous; emtricitabine tenofovir ... See more keywords
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
Sign Up to like & getrecommendations! Published in 2019 at "AIDS Research and Human Retroviruses"
DOI: 10.1089/aid.2019.0111
Abstract: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented. Postbaseline samples for… read more here.
Keywords: emtricitabine tenofovir; resistance; tenofovir; week ... See more keywords
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkw439
Abstract: ical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol 2010; 27: 221–4. 5 Wirden M, Tubiana R, Fourati S et al. Upgraded Cobas Ampliprep-Cobas Taqman version 2.0 HIV-1 RNA quantification assay… read more here.
Keywords: efficacy elvitegravir; hiv; elvitegravir cobicistat; tenofovir disoproxil ... See more keywords
Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.
Sign Up to like & getrecommendations! Published in 2018 at "AIDS"
DOI: 10.1097/qad.0000000000001913
Abstract: The impact of bariatric surgery on antiretroviral pharmacokinetics is poorly documented. Common surgical interventions for morbid obesity include diversionary procedures such as Roux-en-Y gastric bypass (RYGB) and restrictive procedures such as sleeve gastrectomy. Both procedures… read more here.
Keywords: bypass; surgery; darunavir emtricitabine; boosted darunavir ... See more keywords
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients.
Sign Up to like & getrecommendations! Published in 2019 at "AIDS"
DOI: 10.1097/qad.0000000000002463
Abstract: BACKGROUND Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10mg was investigated through 96 weeks in AMBER (NCT02431247). METHODS Treatment-naïve, HIV-1-positive adults (screening plasma viral load [VL]≥1000 copies/ml; CD4 count >50 cells/mm) were randomized (1:1) to D/C/F/TAF (N=362) or D/C… read more here.
Keywords: week results; emtricitabine tenofovir; darunavir; tenofovir ... See more keywords
Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV
Sign Up to like & getrecommendations! Published in 2023 at "AIDS"
DOI: 10.1097/qad.0000000000003513
Abstract: Objective: To evaluate the safety and efficacy of switching highly treatment-experienced people with HIV (HTE PWH) from rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) plus dolutegravir (DTG) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus doravirine (DOR). A pharmacokinetic (PK) analysis was… read more here.
Keywords: taf plus; emtricitabine tenofovir; ftc taf; treatment ... See more keywords
Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance
Sign Up to like & getrecommendations! Published in 2022 at "HIV Medicine"
DOI: 10.1111/hiv.13376
Abstract: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is approved for treatment of HIV without known resistance to its components. Several studies have demonstrated efficacy of B/F/TAF in patients with nucleoside reverse transcriptase inhibitor (NRTI) resistance‐associated mutations (RAMs), mainly identified… read more here.
Keywords: emtricitabine tenofovir; nrti resistance; bictegravir emtricitabine; resistance ... See more keywords
Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm13040583
Abstract: In this observational study, we aimed to evaluate whether bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered 5 or 4 days a week is able to maintain viral suppression in people living with HIV (PLHIV). We enrolled 85 patients… read more here.
Keywords: emtricitabine tenofovir; people living; bictegravir emtricitabine; viral suppression ... See more keywords
Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort
Sign Up to like & getrecommendations! Published in 2023 at "Viruses"
DOI: 10.3390/v15061222
Abstract: Background: Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single-tablet regimen for the treatment of people living with HIV (PLWH). We aimed to assess efficacy, safety, and tolerability of BIC/FTC/TAF among PLWH, with a specific… read more here.
Keywords: plwh; switch; emtricitabine tenofovir; bictegravir emtricitabine ... See more keywords